• Channels
    • All News
    • In Focus
    • Special
    • AI
    • Bioregnum
    • Biotech Voices
    • Cell/Gene Tx
    • China
    • Coronavirus
    • Deals
    • Diagnostics
    • Discovery
    • FDA+
    • Financing
    • Health Tech
    • Law
    • Letters to the Editor
    • Manufacturing
    • Marketing
    • Nikkei Biotechnology
    • Opinion
    • Outsourcing
    • Peer Review
    • People
    • Pharma
    • R&D
    • Startups
    • Weekly
  • Webinars
  • Biopharma Jobs
  • More
    • Work at Endpoints
    • Letter to Editors
    • Editorial Standards
    • IPO Tracker
    • Webinars
    • Events
    • Sponsored Posts
    • Advertise
    • Privacy Policy
    • Endpoints Merch
    • About Us
    • Help
  • SIGN UP

As­traZeneca un­veils its brand new open-of­fice cen­ter in the Bay Area. Do you love it, or hate it?

7 years ago
R&D

Au­toim­mune biotech Kiniksa prices up­sized $152M IPO as Schol­ar Rock bags $75M for pre­clin­i­cal SMA drug

7 years ago
Financing

Aptinyx looks to bring its NM­DA pipeline to Nas­daq, fil­ing for an $80 mil­lion IPO

7 years ago
Financing

This start­up CEO swift­ly gained $260M and a dream team of biotech back­ers — on both sides of the Pa­cif­ic

7 years ago
Startups

Astel­las shed­ding 600-plus jobs as CEO shakes up R&D and sales ops in re­struc­tur­ing

7 years ago
R&D
Pharma

Ox­ford spin­out grabs $9M A round for pep­tide plat­form; blue­bird gets a 'break­through' at the FDA

7 years ago
News Briefing

New PhI­II gives Es­pe­ri­on's CEO a chance to push back against a le­gion of crit­ics — but can he win back in­vestors?

7 years ago
R&D

Mer­ck crush­es Keynote-407 study in front­line lung can­cer, hit­ting co-pri­maries and set­ting up an­oth­er quick OK

7 years ago
R&D

30-year Gilead R&D vet Nor­bert Bischof­berg­er is start­ing over as staffer #5 at an up­start biotech — and he’s ...

7 years ago
People
Startups

Cara hauls in $70M on first leg of glob­al deal, set­ting up PhI­II kid­ney dis­ease drug for com­mer­cial roll out

7 years ago
R&D
Pharma

Ver­sant backs new ap­proach to gam­ma delta T cells, co-leads Lava's $18.9M round

7 years ago
Financing
Startups

House pass­es 'right-to-try' — al­low­ing the ter­mi­nal­ly ill to ask com­pa­nies for ex­per­i­men­tal drugs out­side of FDA's ...

7 years ago
Pharma

FDA chief Got­tlieb is build­ing a reg­u­la­to­ry speed­way to ac­cel­er­ate gene ther­a­py de­vel­op­ment

7 years ago
Pharma
Cell/Gene Tx

Take­da bags $280M, sells off its stake in a Chi­na drug JV ahead of $62B Shire buy­out

7 years ago
Deals

Gates Foun­da­tion, UK gov­ern­ment back CARB-X, boost an­tibi­otics fund­ing past $500M

7 years ago
News Briefing

Fight­ing for a place in the ul­cer­a­tive col­i­tis mar­ket, Sub­lim­i­ty rais­es $64M for an al­ter­na­tive drug to an­ti-TNF

7 years ago
Financing

Sesen's PhI­II blad­der can­cer da­ta send stock south as in­vestors fret over safe­ty

7 years ago
R&D

Al­ler­gan dou­bles down on NM­DA de­pres­sion drug de­vel­op­ment ef­forts, bag­ging an op­tion to a small mol­e­cule fol­lowup ...

7 years ago
R&D
Pharma

Buoyed by he­mo­phil­ia A gene ther­a­py up­date, Bio­Marin switch­es to head-to-head study -- but shares slide on dura­bil­i­ty ...

7 years ago
R&D

Grail hauls in mon­ster $300M round from Chi­nese in­vestors amid ru­mors about Hong Kong IPO

7 years ago
Financing
China

New­com­er Do­va hus­tles a phar­ma castoff through to an FDA ap­proval, shares sink any­way

7 years ago
Pharma

Hunt­ing a cure, Spark re­ports steady progress on he­mo­phil­ia B gene ther­a­py as Pfiz­er preps for piv­otal hand­off

7 years ago
R&D

Wrestling with set­backs, Cel­gene adds $65M dis­cov­ery al­liance with Evotec to beef up on new can­cer drugs

7 years ago
R&D
Pharma

Bay Area start­up Rain Ther­a­peu­tics nabs $18M Se­ries A to tar­get lung can­cer niche

7 years ago
Financing
Startups
First page Previous page 1025102610271028102910301031 Next page Last page
Endpoints News

Bioscience & Technology Business Center
The University of Kansas
Lawrence, Kansas

Latest

  • All News
  • Special
  • In Focus

Channels

  • AI
  • Bioregnum
  • Biotech Voices
  • Cell/Gene Tx
  • China
  • Coronavirus
  • Deals
  • Diagnostics
  • Discovery
  • FDA+
  • Financing
  • Health Tech
  • Law
  • Letters to the Editor
  • Manufacturing
  • Marketing
  • Nikkei Biotechnology
  • Opinion
  • Outsourcing
  • Peer Review
  • People
  • Pharma
  • R&D
  • Startups
  • Weekly

More

  • Work at Endpoints
  • Letter to Editors
  • Editorial Standards
  • IPO Tracker
  • Events
  • Webinars
  • Sponsored Posts
  • Advertise
  • Endpoints Merch
  • About Us
  • Help

Work in biotech

  • Endpoints Careers

© Endpoints News 2025

  • Help
  • Advertise
  • Privacy Policy
  • Business Model
FT Specialist Logo
A service from the Financial Times
Endpoints News

Log in to your account

email

password

Endpoints News

request login link

Enter the email associated to with your Endpoints account, and we'll send you a one-time login link (no password needed). The link expires after 24 hours.

email

Endpoints News

reset password

Enter the email associated to with your Endpoints account, and we'll send you a link to reset your password. The link expires after 24 hours and can only be used once.

email

Endpoints News

Sign up for free to read a limited number of articles each month.

About You

Newsletter Interests

Pick what newsletters get delivered to your inbox each week.

Biopharma

ENDPOINTS NEWS Daily at 11:30 AM ET

EARLY EDITION Daily at 7:15 AM ET

ENDPOINTS PHARMA Daily at 3:30 PM ET

BREAKING NEWS ALERTS 2-3 times a week

ENDPOINTS FDA+ Wed at 2 PM ET

ENDPOINTS MANUFACTURING Thu at 2 PM ET

ENDPOINTS WEEKLY Sat at 6 AM ET

POST-HOC 1-2 times a week

Healthcare

ENDPOINTS HEALTH TECH Tuesday, Thursday at 10 AM ET

BREAKING NEWS ALERTS 2-3 times a week

Want unlimited access? Sign up for a premium subscription plan.